View:
Download DOC
Download PDF
Download XLS
Form 8-K
 
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 22, 2009 (May 15, 2009)

Lifevantage Corporation
 (Exact name of registrant as specified in its charter)

         
Colorado   000-30489   90-0224471
(State or other Jurisdiction of Incorporation)   (Commission File Number)   (IRS Employer Identification No.)
     
11545 W. Bernardo Court, Suite 301, San Diego, California
  92127
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s telephone number, including area code: (858) 312-8000

 
 
(Former name or former address if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 

 

1

 

Item 2.02 Results of Operations and Financial Conditions

On May 15, 2009, Lifevantage Corporation issued a press release entitled, “Lifevantage Corporation Announces 3Q FY 2009 Financial and Operating Results”. The press release is attached as Exhibit 99.1 hereto, which is furnished under Item 2.02 of this report and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”) or the Exchange Act, regardless of any general incorporation language in such filing.

Item 7.01 Regulation FD Disclosure

On May 15, 2009, Lifevantage Corporation issued a press release entitled, “Lifevantage Corporation Announces 3Q FY 2009 Financial and Operating Results”.  The press release is attached as Exhibit 99.1 hereto, which is furnished under Item 7.01 of this report and shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, regardless of any general incorporation language in such filing. On May 19, 2009, Lifevantage Corporation held a conference call in connection with the press release.  Information on how to access a replay of the call can be found on the Company’s website at www.lifevantage.com on the “Investor Info” page located under the “Company” tab, until May 29, 2009.

Item 9.01 Exhibits

99.1 Press release, dated May 15, 2009, entitled, “Lifevantage Corporation Announces 3Q FY 2009 Financial and Operating Results”.

 

2

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: May 22, 2009

LIFEVANTAGE CORPORATION

By: /s/ Bradford K. Amman
Bradford K. Amman
Chief Financial Officer

 

3

 

EXHIBIT INDEX

99.1   Press release, dated May 15, 2009, entitled, “Lifevantage Corporation Announces 3Q FY 2009 Financial and Operating Results”.

 

4

Exhibit 99.1
Exhibit 99.1
(LOGO)
     
FOR IMMEDIATE RELEASE
  NEWS
May 15, 2009
  OTCBB: LFVN
LIFEVANTAGE CORPORATION ANNOUNCES
3Q FY 2009 FINANCIAL AND OPERATING RESULTS
SAN DIEGO, California — LifeVantage Corporation (OTCBB: LFVN), maker of Protandim®, today announced results for its third quarter ended March 31, 2009. For the three month period ended March 31, 2009, the Company recorded net revenues of $0.7 million and a loss of $(3.1) million, or $(0.12) per share. For the three month period ended March 31, 2008, the Company recorded net revenues of $0.8 million and a loss of $(0.6) million, or $(0.03) per share.
For the nine month period ended March 31, 2009, the Company recorded net revenues of $2.5 million and a loss of $(3.8) million, or $(0.15) per share, of which approximately $1.5 million, or $0.06 per share consisted of non-cash expenses. Additionally, approximately $0.5 million, or $0.02 per share consisted of one-time expenses. This compares to net revenues of $2.4 million and a loss of $(1.3) million, or $(0.06) per share for the nine month period ended March 31, 2008.
LifeVantage President and CEO, David W. Brown, commented, “During the third quarter the Company has been preparing for our entry into network marketing. We successfully raised capital through a private offering in order to meet the increased expenditures we knew would be necessary to strengthen our infrastructure, increase inventories, develop new marketing tools and to recruit new distributors. The third quarter results reflect the costs of preparing the Company for significant anticipated growth, and we believe that the greatly increased interest in our Company reflects the fact that there is much excitement about the steps we have taken and the progress we’ve made.”
The Company also announced that on May 18, it will officially launch its new distributor compensation plan, as well as its highly anticipated new anti-aging skin cream, and will begin fulfilling the orders it has received, but not shipped or booked during this pre-launch period. Brown stated, “We have created impressive momentum. Approximately 2,000 distributors have already joined the Company, drawn by the science of our flagship product, Protandim®, the attractiveness of the business opportunity and the strength of our management team. We are attracting both distributors who have been tremendously successful in network marketing, as well as those who are entirely new to the industry and who are excited about the opportunity.”
Other significant developments in the past quarter include the retention of a country manager for Mexico and the filing for product registration in Mexico; the addition of internationally-known physicians, Dr. David Perlmutter and Dr. Arnold Leonard, to the Company’s Scientific Advisory Board; Emmy award-winning talk show host Montel Williams joined LifeVantage as an independent distributor; and a new peer reviewed study on Protandim® was released by Louisiana State University. Approximately 20 additional studies are being independently funded and conducted at academic institutions and research facilities across the nation.

 

1

 

A conference call will be held on Tuesday, May 19, 2009, at 2:00 p.m. MT (4:00 p.m. ET) to discuss its third quarter fiscal year 2009 financial and operating results and its launch into network marketing. Interested parties may listen to the call by dialing 1-877-941-2928. A replay of the call will be available by telephone until May 26, 2009, at 1-800-406-7325 passcode 4081184.
About Protandim®
Protandim® is a groundbreaking, clinically proven supplement that provides a substantial benefit to help with the challenge of healthy aging. This patented antioxidant therapy works in a very different way than conventional foods such as red wine, oranges, blueberries or other popular antioxidant supplements; as a result, according to Dr. Joe McCord, is much more effective than those products or foods in reducing oxidative stress. Protandim® works by increasing the body’s natural antioxidant protection at the cellular level, triggering cells to produce naturally occurring protective antioxidant enzymes such as superoxide dismutase (SOD), catalase, and glutathione synthase. Dr. McCord is a pioneer scientist in the field of oxidative stress and is on the Company’s Board of Directors.
A peer-reviewed human study showed that after Protandim® was taken for 30 consecutive days, the accumulation of lipid peroxidation products (a biochemical marker of aging) was decreased by an average of 40%, although that reduction may be not be typical for all those who consume the product. The study also reported that this important marker of aging was decreased after taking Protandim® to the level of a typical 20 year old. Protandim® is currently the subject of over 20 scientific studies at leading universities and research facilities. For more information, please visit www.LifeVantage.com or contact Jan Strode (619) 890-4040 or Jean Golden (612) 385-2324.
About LifeVantage Corporation
LifeVantage Corporation is a publicly traded (OTCBB: LFVN), science-based, natural products company, dedicated to helping people reach their health and wellness goals through science-based solutions to oxidative stress. Founded in 2003 and based in San Diego, CA, LifeVantage develops nutraceutical products, including Protandim®, that leverage the company’s expertise and that are intended to deliver significant health benefits to consumers. For more information, visit www.LifeVantage.com or contact Jan Strode (619) 890-4040 or Jean Golden (612) 385-2324.
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on the Company’s current expectations and beliefs concerning future events affecting the Company and involve known and unknown risks and uncertainties including the risk that sales of our product may not continue at the levels discussed in this press release. These risks and uncertainties may cause the Company’s actual results or outcomes to be materially different from those anticipated and discussed herein. These and other risk factors are discussed in greater detail in the Company’s Annual Report on Form 10-KSB for the year ended June 30, 2008, the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2009 and in other documents filed by the Company from time to time with the Securities and Exchange Commission. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. All forward-looking statements are based on information currently available to the Company, and the Company undertakes no obligation to revise or update these forward-looking statements.
# # #

 

2

 

CONTACTS:
LifeVantage Corporation
Jan Strode, Investor Relations     Telephone: (619) 890-4040
Jean Golden, Investor Relations     Telephone: (612) 385-2324
Bradford Amman, CFO     Telephone: (303) 797-9977

 

3

 

LIFEVANTAGE CORPORATION AND SUBSIDIARY
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)
                 
    March 31, 2009     June 30, 2008  
ASSETS
                
Current assets
                
Cash and cash equivalents
   $ 1,312,793     $ 196,883  
Restricted cash
     770,000       —  
Marketable Securities, available for sale
     580,000       1,100,000  
Accounts receivable, net
     90,432       98,008  
Inventory
     457,083       104,415  
Deferred expenses
     —       72,049  
Deposit with manufacturer
     6,482       277,979  
Prepaid expenses
     38,612       124,049  
 
            
Total current assets
     3,255,402       1,973,383  
Long-term assets
                
Marketable Securities, available for sale
     145,000       —  
Property and equipment, net
     171,929       63,559  
Intangible assets, net
     2,194,478       2,270,163  
Deferred debt offering costs, net
     129,342       193,484  
Deposits
     48,263       48,447  
 
            
TOTAL ASSETS
   $ 5,944,414     $ 4,549,036  
 
            
LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY
                
Current liabilities
                
Revolving line of credit and accrued interest
   $ 325,146     $ 166,620  
Accounts payable
     899,465       139,803  
Accrued expenses
     779,428       338,268  
Deferred revenue
     —       510,765  
Capital lease obligations
     —       846  
Equity escrow
     770,000       —  
 
            
Total current liabilities
     2,774,039       1,156,302  
Long-term liabilities
                
Convertible debt, net of discount
     348,175       223,484  
Derivative warrant liability
     7,247,885       —  
 
            
Total liabilities
     10,370,099       1,379,786  
 
            
Commitments and contingencies
                
Stockholders’ (deficit) equity
                
Preferred stock — par value $.001, 50,000,000 shares authorized; no shares issued or outstanding
     —       —  
Common stock — par value $.001, 250,000,000 shares authorized; 38,250,402 and 24,766,117 issued and outstanding as of March 31, 2009 and June 30, 2008, respectively
     38,250       24,766  
Additional paid-in capital
     14,091,899       17,902,840  
Accumulated (deficit)
     (18,555,834 )     (14,758,356 )
 
            
Total stockholders’ (deficit) equity
     (4,425,685 )     3,169,250  
 
            
TOTAL LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY
   $ 5,944,414     $ 4,549,036  
 
            
The notes accompanying Form 10-Q are an integral part of these condensed consolidated statements.

 

4

 

LIFEVANTAGE CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
                                 
    For the three months ended     For the nine months ended  
    March 31,     March 31,  
    2009     2008     2009     2008  
Sales, net
   $ 655,122     $ 783,946     $ 2,507,083     $ 2,387,677  
Cost of sales
     125,198       174,890       488,283       538,212  
 
                        
Gross profit
     529,924       609,056       2,018,800       1,849,465  
 
                                
Operating expenses:
                                
Marketing and customer service
     1,019,739       357,990       1,826,608       1,021,111  
General and administrative
     1,885,630       702,404       2,896,456       1,606,926  
Research and development
     34,427       25,045       152,942       243,934  
Depreciation and amortization
     40,653       39,581       120,081       117,988  
 
                        
Total operating expenses
     2,980,449       1,125,020       4,996,087       2,989,959  
 
                        
Operating (loss)
     (2,450,525 )     (515,964 )     (2,977,287 )     (1,140,494 )
 
                                
Other income and (expense):
                                
Interest (expense), net
     (148,935 )     (88,692 )     (319,319 )     (164,647 )
Change in fair value of derivative liability
     (500,862 )     —       (500,862 )     —  
 
                        
Total other (expense)
     (649,797 )     (88,692 )     (820,181 )     (164,647 )
 
                        
Net (loss)
   $ (3,100,332 )   $ (604,656 )   $ (3,797,468 )   $ (1,305,141 )
 
                        
Net (loss) per share, basic and diluted
     ($0.12 )     ($0.03 )     ($0.15 )     ($0.06 )
 
                        
Weighted average shares outstanding, basic and fully diluted
     25,973,085       22,464,168       25,165,481       22,349,282  
 
                        
The notes accompanying Form 10-Q are an integral part of these condensed consolidated statements.

 

5